Clinical Trials
- Head and Neck Cancers, Phase 1 Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Ages18 years and older
- GenderBoth
- Date12/17/2019
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Date07/05/2019
- Thyroid and Other Endocrine Cancers
A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
- Ages18 years and older
- GenderBoth
- Date04/09/2018
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
- Date12/18/2017
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Lung Cancer, Other Cancers, Pancreatic Cancer, Prostate Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Ages18 years and older
- GenderBoth
- Date11/20/2017
- Gynecological Cancers, Thyroid and Other Endocrine Cancers
Endometrium and Metabolism
- Date12/14/2018
- Bladder Cancer, Brain and Other Nervous System Cancers, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
- Date08/08/2016
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Date01/04/2019
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
Phase I-II Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
- Ages18 years and older
- GenderBoth
- Date04/15/2016
- Bladder Cancer, Brain and Other Nervous System Cancers, Colorectal Cancer, Gynecological Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Other Cancers, Pediatric Cancers, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Date04/18/2016